Your Blood Is Thicker Than It Should Be. Here's the Genetic Reason.

Factor V is a critical blood clotting protein that amplifies the clotting cascade, helping your body form stable blood clots when you bleed. It’s essential for normal wound healing. Without functional Factor V, you’d bleed uncontrollably.

The Factor V Leiden variant (R506Q) is carried by roughly 5% of people with European ancestry. This variant makes Factor V resistant to the protein that normally breaks clots down (activated protein C). The result is that your blood clots form more easily and dissolve more slowly, increasing your venous thromboembolism risk by 4 to 8 times. For women on oral contraceptives, the risk jumps to 80-fold.

You might notice swelling in one leg that doesn’t match the other, a feeling of heaviness or warmth, or pain that comes and goes in your calf or thigh. Long flights or immobility worsen the sensation. This is your body trying to tell you that clots are forming more readily than they should be.

Prothrombin (Factor II) is the starting enzyme in your clotting cascade. It converts fibrinogen into fibrin, the protein that forms the physical structure of a blood clot. Prothrombin is essential for normal clotting, but too much of it accelerates clot formation dangerously.

The G20210A variant is found in roughly 2 to 3% of people with European ancestry. This variant increases prothrombin production, raising circulating prothrombin levels and increasing your clotting risk by 2 to 3 times. When combined with Factor V Leiden or other clotting variants, the risk compounds significantly.

You might experience recurrent leg swelling, a persistent sense of heaviness even when you’re moving regularly, or a history of blood clots that doctors attributed to bad luck or dehydration. The variant makes your blood “sticky” at the molecular level.

MTHFR catalyzes a critical step in the methylation cycle, converting folate into its active form so your cells can regulate homocysteine. Homocysteine is an amino acid; at healthy levels, it’s harmless. When it accumulates, it damages blood vessel walls and promotes clot formation. MTHFR variants reduce enzyme efficiency, allowing homocysteine to rise.

The C677T variant is carried by roughly 40% of people with European ancestry. This variant reduces MTHFR enzyme activity by 40 to 70%, causing homocysteine to accumulate in your blood. Elevated homocysteine is an independent cardiovascular risk factor that contributes to both atherosclerosis and thrombosis. Many people with this variant have never had their homocysteine measured.

You might experience fatigue that doesn’t match your activity level, brain fog that worsens despite good sleep, or a sense that your circulation is sluggish. Combined with other clotting variants, MTHFR C677T significantly raises your overall risk.

PAI-1 is an inhibitor of fibrinolysis, the process that breaks down blood clots after they’ve served their purpose. In healthy amounts, PAI-1 prevents excessive bleeding. In excess, it prevents clots from dissolving, leaving them to accumulate and potentially travel to your lungs or brain.

The 4G/5G polymorphism determines PAI-1 production levels. People with the 4G/4G genotype, found in roughly 25% of the population, produce more PAI-1 than 5G carriers. High PAI-1 levels slow clot breakdown, increasing your thrombosis risk and cardiovascular event risk by approximately 1.5 to 2 times. This variant is particularly dangerous when combined with other clotting factors like F5 or F2 variants.

You might notice that even minor injuries take longer to heal completely, or that you feel a persistent heaviness in your legs despite normal activity. Your blood is literally slower to dissolve clots, creating a backlog.

Nitric oxide (NO) is a signaling molecule produced by blood vessel lining cells. It causes blood vessels to dilate, improves blood flow, and actively inhibits clotting. When nitric oxide production is high, your blood vessels relax and clots are less likely to form. NOS3 is the enzyme that produces most of this nitric oxide.

The Glu298Asp variant (rs1799983) is carried by roughly 30 to 40% of the population. This variant reduces NOS3 enzyme activity, causing lower nitric oxide production in your blood vessels. The result is impaired vessel dilation, increased blood viscosity perception, and a higher risk of hypertension and atherosclerotic clot formation. Your vessels are literally less able to relax and dilate, trapping blood.

You might experience leg cramps or heaviness that worsens with stress, a feeling that your circulation tightens when you’re anxious, or elevated blood pressure that doesn’t respond well to standard medications. Your vessels are not relaxing properly.

VKORC1 is the enzyme that recycles vitamin K after it’s been used in clotting factor production. Vitamin K is a fat-soluble vitamin essential for activating clotting factors II, VII, IX, and X. VKORC1 efficiency determines how much vitamin K your body needs and how sensitive you are to anticoagulant medications.

VKORC1 has several common variants, particularly in the promoter region (rs9923231 and others). These variants alter VKORC1 expression, meaning roughly 30 to 50% of people carry efficiency variants. People with low-expression variants need less vitamin K to maintain normal clotting and are more sensitive to warfarin, requiring lower doses. People with high-expression variants are warfarin-resistant and require higher doses.

You might not notice VKORC1 variants in daily life unless you take warfarin or another vitamin K-dependent anticoagulant. If you do, the difference is critical: wrong dosing can mean clots or excessive bleeding. Even your dietary vitamin K intake affects your clotting balance more dramatically with this variant.